Every material Form 8-K Decoy Therapeutics Inc. has filed with the SEC since May 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.
1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.
Decoy Therapeutics entered into a securities purchase agreement on June 26, 2026 to sell 592,217 shares of common stock at $5.91 per share to one institutional investor, with closing expected on or about June 29, 2026. The deal also includes milestone-based warrants that could bring up to about $17.5 million more in gross proceeds if exercised, which would add to existing shareholder dilution and depends on future milestones and stockholder approval.
Expected gross proceeds of about $3.5 million before placement agent fees and offering expenses
592,217 shares priced at $5.91 per share, with pre-funded warrants available to the investor in lieu of shares
Series A, B and C milestone warrants could add up to about $17.5 million if fully exercised after milestones and stockholder approval
Placement agent Curvature Securities receives a 9.0% cash fee; a resale registration statement is due within 15 calendar days of the registration rights agreement
Decoy Therapeutics set July 14, 2026 as the date of its 2026 Annual Meeting of Stockholders, and disclosed new deadlines for stockholder proposals and director nominations. The filing is procedural: it tells shareholders when they must act to present proposals or nominees, and that meeting details will come in a later proxy statement.
Board set July 14, 2026 as the 2026 Annual Meeting date, on May 12, 2026
Stockholders of record at close of business on May 22, 2026 are entitled to vote
Deadline for Rule 14a-8 proposals for the proxy statement is close of business on May 29, 2026
Advance notice deadline for other proposals and director nominations is May 29, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Decoy Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →